Abstract 5760
Background
PD-L1 expression was approved by U.S. FDA as companion or complementary diagnostic for most anti-PD-1/ PD-L1 inhibitors, which is well accepted as one of the important biomarkers in the selection of patients who would have high potential to respond. By far, the PD-L1 prevalence in Chinese solid tumor patients is poorly reported. In lung cancer, the correlation between PD-L1 expression and another important biomarker tumor mutation burden (TMB) has been demonstrated to be weak, however, the results in other types of solid tumor are still limited, which needs further explorations.
Methods
A total of 6,571 Chinese solid tumor patients, including 1,534 lung cancer patients and 5,037 other solid tumor patients, from 70 sites were studied. The tissue samples, either surgical resection specimens or biopsy samples, were both stained by clinical validated PD-L1 IHC assay and performed the next generation sequencing (NGS) using a validated commercial 381-cancer-gene panel, with panel size over 0.5 MB. TMB was calculated according to NGS results.
Results
835 of 1534 (54.4%) lung cancer patients had PD-L1 expression >1% on tumor cells. The PD-L1 prevalence in NSCLC, small cell lung cancer, squamous cell carcinoma, adenocarcinoma and adenosine squamous cell carcinoma were 55.4%, 16.1%, 64.2%, 52.7% and 66.7%, respectively. Among 5,037 non-lung solid tumor patients, the proportion of PD-L1 expression >1% is 28.4%, 23.5%, 38.9%, 29.5%, 60% and 37.1% in gastric cancer, colorectal cancer, hepatobiliary cancer, urologic cancer, head and neck cancer and gynecological cancer. The average TMB of PD-L1 expression >1% solid tumor patients (excluding lung cancer) was 10.87/ MB, which is statistically significant higher than PD-L1 expression <1% subgroup (8.64/MB, p = 2.5e-06).
Conclusions
The PD-L1 prevalence varied in different tumor type subgroups. And TMB was significant different between PD-L1 expression >1% and <1% subgroups. But, the correlation between PD-L1 and TMB needs more studies, which is important to reveal whether these two biomarkers are mutually independent.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
3D Medicine, Shanghai.
Funding
3D Medicine, Shanghai.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2316 - A 3D co-culture platform of breast cancer and patient derived immune cells to analyse the response to chemotherapy and immunotherapies
Presenter: Diana Saraiva
Session: Poster Display session 3
Resources:
Abstract
4290 - Characterization of the mechanism of action and efficacy of MEN1611 (PA799), a novel PI3K inhibitor, in breast cancer preclinical models.
Presenter: Alessio Fiascarelli
Session: Poster Display session 3
Resources:
Abstract
2167 - Neat-1: culprit lnRNA tying PIG-C, MSLN, CD80 in TNBC
Presenter: Nada Hussein
Session: Poster Display session 3
Resources:
Abstract
1829 - A novel RAF/MEK inhibitor CH5126766 in phase 1 clinical trial has an effectiveness in the combination with eribulin for the treatment of triple negative breast cancer
Presenter: Hisako Ono
Session: Poster Display session 3
Resources:
Abstract
4357 - Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer
Presenter: Eva Galan-Moya
Session: Poster Display session 3
Resources:
Abstract
5163 - Preclinical Evaluation targeting both IGF1R and IR in Triple Negative Breast Cancer
Presenter: Alex Eustace
Session: Poster Display session 3
Resources:
Abstract
832 - Monospecific antibody targeting of CDH11 inhibits epithelial-to-mesenchymal transition and represses cancer stem cell-like phenotype by up-regulating miR-335 in metastatic breast cancer, in vitro and in vivo.
Presenter: Jia-Hong Chen
Session: Poster Display session 3
Resources:
Abstract
3781 - Pharmacological screening with Chk1 inhibitors identify synergistic agents to overcome resistance to platinums in basal breast and ovarian cancer
Presenter: Ana Lucia Sanabria
Session: Poster Display session 3
Resources:
Abstract
3275 - Comparison of 11 circulating miRNAs and CA125 kinetics in ovarian cancer during first line treatment: data from the randomized CHIVA trial (a GINECO-GCIG study)
Presenter: Patrick Robelin
Session: Poster Display session 3
Resources:
Abstract
3391 - Inhibiting Ehmt2 and Ezh2 histone methyltransferases alters the immune microenvironment in a Trp53-/- murine ovarian cancer model
Presenter: Pavlina Spiliopoulou
Session: Poster Display session 3
Resources:
Abstract